[New antibiotics prior to approval: is this the end of the innovative stagnation?].
Therapeutic efficacy and safety in infections due to multiresistant bacteria can be improved by the clinical development of new compounds and devising new derivatives of already useful antibiotics. Due to a striking global increase of multiresistant gram-negative and gram-positive organisms, new antibiotics are urgently needed. This paper provides a review of new pharmaceuticals which are already in clinical development, mainly in phase III trials. Each of these new trials increases the possibility of new antibiotics receiving approval.